# Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer

> **NCT05578053** · — · RECRUITING · sponsor: **Hebei Medical University Fourth Hospital** · enrollment: 420 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Dalpiciclib

## Key facts

- **NCT ID:** NCT05578053
- **Lead sponsor:** Hebei Medical University Fourth Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-13
- **Primary completion:** 2028-12-01
- **Final completion:** 2030-12-01
- **Target enrollment:** 420 (ESTIMATED)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05578053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05578053, "Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05578053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*